<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011411</article-id><article-id pub-id-type="publisher-id">ACM-38813</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_55877952.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  磺达肝癸钠和依诺肝素对NSTE-ACS保守治疗老年患者的临床研究
  Clinical Study on the Conservative Treatment of NSTE-ACS in Elderly Patients with Sodium Sulfonate and Enoxaparin
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>喆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>术</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>管</surname><given-names>甲亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>永彬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>学志</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>秦</surname><given-names>桥基</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>新涛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>荆</surname><given-names>丽宏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>长勇</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院检验科，山东 青岛</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院心血管内科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属医院急诊内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2705</fpage><lpage>2709</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析老年NSTE-ACS患者选择保守治疗后应用磺达肝癸钠和依诺肝素治疗的有效性和安全性。方法：选取我院急诊科收治的176名NSTE-ACS选择保守治疗的老年患者作为研究对象，根据患者应用不同的抗凝药物，将其随机分为磺达肝癸钠组(n = 87)和依诺肝素组(n = 89)，观察和比较两组患者在住院期间内主要疗效终点及安全性终点的发生率。结果：比较两组患者主要疗效终点的发生率，差异无统计学意义(P &gt; 0.05)。磺达肝癸钠组轻度出血的发生率低于依诺肝素组(P &lt; 0.05)。严重出血的发生率，两组间差异无统计学意义(P &gt; 0.05)。结论：对于NSTE-ACS选择保守治疗的老年患者，在住院期间内，磺达肝癸钠和依诺肝素具有相当的临床疗效，但是磺达肝癸钠要比伊诺肝素更加安全。
    Objective: To analyze the efficacy and safety of fondaparinux sodium and enoxaparin in elderly NSTE-ACS patients during conservative treatment. Methods: Selecting 176 elderly patients with NSTE-ACS who chose conservative treatment in our hospital emergency department as the research object, according to the application of different anticoagulant drugs, patients were randomly divided into the fondaparinux sodium group (n = 87) and the enoxaparin group (n = 89). The incidence of primary efficacy and safety endpoints during hospitalization between the two groups was observed and compared. Results: There was no statistically significant difference between the two groups in the incidence of the main therapeutic end points (P &gt; 0.05). The incidence of mild bleeding in the fondaparinux sodium group was lower than that in the enoxaparin group (P &lt; 0.05). There was no significant difference in the incidence of severe bleeding between the two groups (P &gt; 0.05). Conclusion: In elderly patients with conservative treatment of NSTE-ACS, fondaparinux sodium and enoxaparin have significant clinical efficacy during hospitalization, but fondaparinux is safer than enoxaparin. 
  
 
</p></abstract><kwd-group><kwd>磺达肝癸钠，依诺肝素，非ST段抬高型急性冠脉综合征, Fondaparinux Sodium</kwd><kwd> Enoxaparine</kwd><kwd> NSTE-ACS</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析老年NSTE-ACS患者选择保守治疗后应用磺达肝癸钠和依诺肝素治疗的有效性和安全性。方法：选取我院急诊科收治的176名NSTE-ACS选择保守治疗的老年患者作为研究对象，根据患者应用不同的抗凝药物，将其随机分为磺达肝癸钠组(n = 87)和依诺肝素组(n = 89)，观察和比较两组患者在住院期间内主要疗效终点及安全性终点的发生率。结果：比较两组患者主要疗效终点的发生率，差异无统计学意义(P &gt; 0.05)。磺达肝癸钠组轻度出血的发生率低于依诺肝素组(P &lt; 0.05)。严重出血的发生率，两组间差异无统计学意义(P &gt; 0.05)。结论：对于NSTE-ACS选择保守治疗的老年患者，在住院期间内，磺达肝癸钠和依诺肝素具有相当的临床疗效，但是磺达肝癸钠要比伊诺肝素更加安全。</p></sec><sec id="s2"><title>关键词</title><p>磺达肝癸钠，依诺肝素，非ST段抬高型急性冠脉综合征</p></sec><sec id="s3"><title>Clinical Study on the Conservative Treatment of NSTE-ACS in Elderly Patients with Sodium Sulfonate and Enoxaparin</title><p>Zhe Li<sup>1</sup>, Chao Shu<sup>2</sup>, Jialiang Guan<sup>1*</sup>, Yongbin Wang<sup>1</sup>, Xuezhi Zhang<sup>3</sup>, Qiaoji Qin<sup>1</sup>, Xintao Tian<sup>1</sup>, Lihong Jing<sup>1</sup>, Changyong Zhou<sup>3</sup></p><p><sup>1</sup>Emergency Internal Medicine, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Laboratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>Vasculocardiology Department, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/45-1571663x5_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 19<sup>th</sup>, 2020; published: Nov. 26<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/45-1571663x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the efficacy and safety of fondaparinux sodium and enoxaparin in elderly NSTE-ACS patients during conservative treatment. Methods: Selecting 176 elderly patients with NSTE-ACS who chose conservative treatment in our hospital emergency department as the research object, according to the application of different anticoagulant drugs, patients were randomly divided into the fondaparinux sodium group (n = 87) and the enoxaparin group (n = 89). The incidence of primary efficacy and safety endpoints during hospitalization between the two groups was observed and compared. Results: There was no statistically significant difference between the two groups in the incidence of the main therapeutic end points (P &gt; 0.05). The incidence of mild bleeding in the fondaparinux sodium group was lower than that in the enoxaparin group (P &lt; 0.05). There was no significant difference in the incidence of severe bleeding between the two groups (P &gt; 0.05). Conclusion: In elderly patients with conservative treatment of NSTE-ACS, fondaparinux sodium and enoxaparin have significant clinical efficacy during hospitalization, but fondaparinux is safer than enoxaparin.</p><p>Keywords:Fondaparinux Sodium, Enoxaparine, NSTE-ACS</p><disp-formula id="hanspub.38813-formula38"><graphic xlink:href="//html.hanspub.org/file/45-1571663x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/45-1571663x8_hanspub.png" /> <img src="//html.hanspub.org/file/45-1571663x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性冠脉综合征(ACS)包括不稳定性心绞痛(UA)、非ST段抬高型心肌梗死(NSTEMI)和ST段抬高型心肌梗死(STEMI)。其中，NSTEMI和UA统称为非ST段抬高型急性冠脉综合征(NSTE-ACS)。目前PCI围术期抗凝治疗的研究比较多，磺达肝癸钠和依诺肝素的抗凝治疗各有其利弊 [<xref ref-type="bibr" rid="hanspub.38813-ref1">1</xref>]。然而，对于NSTE-ACS选择药物保守治疗的老年患者，磺达肝癸钠和依诺肝素的选择目前缺乏有效的临床研究。在本项研究中，将会通过比较应用磺达肝癸钠和依诺肝素抗凝治疗的老年患者的临床数据，分析两种抗凝药物临床应用的有效性和安全性。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选择2016年3月至2018年3月期间我院急诊科收治的NSTE-ACS选择保守治疗的老年患者，共176例。</p></sec><sec id="s6_2"><title>2.2. 纳入和排除标准</title><p>纳入标准：① 年龄 &gt; 60周岁；② 符合《非ST段抬高型急性冠状动脉综合征诊断和治疗指南》的诊断标准 [<xref ref-type="bibr" rid="hanspub.38813-ref2">2</xref>]；③ 临床资料完整者。排除标准：① 非首次行PCI术的患者或既往有冠状动脉搭桥术患者；② 既往明确患有心力衰竭、严重心律失常、先天性心脏病、心肌病、瓣膜病等其他心血管疾病；③ 合并恶性肿瘤、自身免疫性疾病、严重肝肾功能不全、凝血功能障碍等严重全身性疾病。</p></sec><sec id="s6_3"><title>2.3. 入组方法</title><p>将选定的研究对象通过掷硬币法随机分为磺达肝癸钠组(n = 87)和依诺肝素组(n = 89)。两组均接受常规抗血小板、调脂和抗心肌缺血等治疗(包括阿司匹林、氯吡格雷或替格瑞洛、他汀类药物、β受体阻滞剂、ACEI或ARB等)。抗凝治疗方面，磺达肝癸钠组的患者用磺达肝癸钠2.5 mg qd治疗；依诺肝素组应用依诺肝素1 mg/kg q12h治疗，如血清肌酐清除率 &lt; 30 ml/min时，改为1 mg/kg qd治疗。两组抗凝疗程为3至8天。</p></sec><sec id="s6_4"><title>2.4. 观察指标</title><p>① 主要疗效终点的发生率。主要疗效终点包括心绞痛发作、新发心肌梗死、心力衰竭、血运重建、心血管原因死亡。② 主要安全性终点的发生率。主要安全性终点包括轻度出血、严重出血。严重出血包括致命性出血、原发性颅内出血、创伤后症状性颅内出血、腹膜后出血、引起视力丧失的眼内出血等，以及血红蛋白下降 ≥ 3.0 g/dl或输血量 ≥ 2 U等。未达到上述标准的出血定义为轻度出血 [<xref ref-type="bibr" rid="hanspub.38813-ref3">3</xref>]。</p></sec><sec id="s6_5"><title>2.5. 统计学处理</title><p>采用SPSS 19.0统计软件进行统计分析。计量资料表示为均数 &#177; 标准差( x &#175; &#177; s )，使用t检验进行比较。计数资料以百分率表示，使用卡方检验进行比较。以P &lt; 0.05为差异有统计学意义。</p></sec><sec id="s6_6"><title>2.6. 伦理许可</title><p>该研究符合医学伦理委员会要求，伦理审批件号：QYFYWZLL25980。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组基线资料比较</title><p>两组患者的年龄、性别、基础疾病、心率、血压、实验室检查、临床用药等比较，差异均无统计学意义(P &gt; 0.05)，具有可比性。见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of baseline data between the two group</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >磺达肝癸钠组(n = 87)</th><th align="center" valign="middle" >依诺肝素组(n = 89)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁， x &#175; &#177; s )</td><td align="center" valign="middle" >71.86 &#177; 9.27</td><td align="center" valign="middle" >73.01 &#177; 10.14</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >男性(例，%)</td><td align="center" valign="middle" >52 (59.77)</td><td align="center" valign="middle" >55 (61.80)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >NSTEMI(例，%)</td><td align="center" valign="middle" >41 (47.13)</td><td align="center" valign="middle" >45 (50.56)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >UA(例，%)</td><td align="center" valign="middle" >46 (52.87)</td><td align="center" valign="middle" >44 (49.44)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >吸烟史(例，%)</td><td align="center" valign="middle" >47 (54.02)</td><td align="center" valign="middle" >49 (55.06)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >高血压(例，%)</td><td align="center" valign="middle" >55 (63.22)</td><td align="center" valign="middle" >58 (65.17)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >糖尿病(例，%)</td><td align="center" valign="middle" >37 (42.53)</td><td align="center" valign="middle" >36 (40.45)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >心率(次/分， x &#175; &#177; s )</td><td align="center" valign="middle" >87.35 &#177; 10.64</td><td align="center" valign="middle" >90.27 &#177; 12.37</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg， x &#175; &#177; s )</td><td align="center" valign="middle" >146 &#177; 17</td><td align="center" valign="middle" >148 &#177; 19</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >舒张压(mmHg， x &#175; &#177; s )</th><th align="center" valign="middle" >72 &#177; 9</th><th align="center" valign="middle" >73 &#177; 8</th><th align="center" valign="middle" >&gt;0.05</th></tr></thead><tr><td align="center" valign="middle" >血红蛋白(g/L， x &#175; &#177; s )</td><td align="center" valign="middle" >111 &#177; 12</td><td align="center" valign="middle" >108 &#177; 13</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >血清肌酐清除率(ml/min， x &#175; &#177; s )</td><td align="center" valign="middle" >57.38 &#177; 7.29</td><td align="center" valign="middle" >58.51 &#177; 6.94</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >拜阿司匹林</td><td align="center" valign="middle" >87 (100.00)</td><td align="center" valign="middle" >88 (98.88)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >氯吡格雷</td><td align="center" valign="middle" >63 (72.41)</td><td align="center" valign="middle" >66 (74.16)</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >替格瑞洛</td><td align="center" valign="middle" >22 (25.29)</td><td align="center" valign="middle" >21 (23.60)</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两组基线资料比较</p></sec><sec id="s7_2"><title>3.2. 两组抗凝疗程比较</title><p>磺达肝癸钠组抗凝治疗时间为(5.16 &#177; 1.27)天，依诺肝素组抗凝治疗时间为(5.34 &#177; 1.34)天，两组间差异无统计学意义(P &gt; 0.05)。</p></sec><sec id="s7_3"><title>3.3. 两组主要疗效终点和主要安全性终点比较</title><p>在住院期间内，患者的心绞痛发作、新发心肌梗死、心力衰竭、血运重建、心血管原因死亡的发生率方面，磺达肝癸钠组较依诺肝素组低，差异有统计学意义(P &lt; 0.05)。与依诺肝素组相比较，磺达肝癸钠组轻度出血的发生率明显减少，差异有统计学意义(P &lt; 0.05)。磺达肝癸钠组严重出血的发生率较依诺肝素组低，差异有统计学意义(P &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the main therapeutic endpoints and safety endpoints between the two groups (case, %</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >磺达肝癸钠组(n = 87)</th><th align="center" valign="middle" >依诺肝素组(n = 89)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >心绞痛发作</td><td align="center" valign="middle" >30 (34.48)</td><td align="center" valign="middle" >32 (35.96)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >新发心肌梗死</td><td align="center" valign="middle" >5 (5.75)</td><td align="center" valign="middle" >6 (6.74)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >心力衰竭</td><td align="center" valign="middle" >26 (29.89)</td><td align="center" valign="middle" >27 (30.34)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >血运重建</td><td align="center" valign="middle" >14 (16.09)</td><td align="center" valign="middle" >15 (16.85)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >心血管原因死亡</td><td align="center" valign="middle" >2 (2.30)</td><td align="center" valign="middle" >3 (3.37)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >轻度出血</td><td align="center" valign="middle" >2 (2.30)<sup>*</sup></td><td align="center" valign="middle" >9 (10.11)</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >严重出血</td><td align="center" valign="middle" >1 (1.15)</td><td align="center" valign="middle" >2 (2.25)</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表2. 两组主要疗效终点和安全性终点比较(例，%)</p><p>注：与依诺肝素组比较，<sup>*</sup>P &lt; 0.05。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>中国目前每年约有700,000人因冠心病去世，冠心病患者的死亡率逐年上升，ACS是导致冠心病患者死亡的主要原因之一 [<xref ref-type="bibr" rid="hanspub.38813-ref4">4</xref>]。与STEMI患者相比较，NSTE-ACS患者的年龄较大、合并症多，在临床中更为常见，并呈逐年增长的态势 [<xref ref-type="bibr" rid="hanspub.38813-ref5">5</xref>]。当临床诊断为NSTE-ACS后，还需要对患者进行危险度分层，以权衡患者缺血和出血的风险，也有助于临床医生选择早期治疗策略(介入或保守治疗) [<xref ref-type="bibr" rid="hanspub.38813-ref3">3</xref>]。然而，由于NSTE-ACS患者起病急且病情复杂，其治疗策略仍存在许多争议。因此，抗栓治疗对这部分患者来说就显得尤为重要 [<xref ref-type="bibr" rid="hanspub.38813-ref6">6</xref>]。</p><p>抗栓治疗是NSTE-ACS治疗的重点已成共识。许多临床试验表明，低分子肝素比普通肝素治疗NSTE-ACS患者有相同或更好的疗效，而低分子肝素没有肝素诱导的血小板减少的副作用，且不需要监测ACT或APTT，临床使用更为方便 [<xref ref-type="bibr" rid="hanspub.38813-ref7">7</xref>]。因此，推荐使用低分子肝素治疗NSTE-ACS，以替代普通肝素 [<xref ref-type="bibr" rid="hanspub.38813-ref8">8</xref>]，伊诺肝素是一种常用的低分子肝素，国内外权威指南都明确推荐。ESC非ST段抬高型ACS诊断和治疗指南认为：无论治疗策略如何选择，磺达肝癸钠都被认为具有良好的疗效和安全性 [<xref ref-type="bibr" rid="hanspub.38813-ref9">9</xref>]。OASIS-5研究了磺达肝癸钠治疗NSTE-ACS患者的疗效及安全性，与依诺肝素相比，磺达肝癸钠死亡事件主要终点发生率降低了17%，出血事件主要终点发生率降低了48% [<xref ref-type="bibr" rid="hanspub.38813-ref10">10</xref>]。但是，目前的研究主要集中在STEMI和NSTE-ACS患者PCI围术期的抗凝治疗，NSTE-ACS保守治疗的老年患者的抗凝治疗尚缺乏充分、有效的研究。</p><p>本研究比较了磺达肝癸钠和依诺肝素应用于NSTE-ACS保守治疗老年患者的相关资料，分析两种抗凝药物临床应用的有效性和安全性，主要疗效终点及严重出血的发生率无统计学差异，磺达肝癸钠轻微出血的发生率低于依诺肝素。另外，本研究统计的主要安全性终点的发生率比以往研究略高，可能与本研究所选对象的年龄、肾功能水平有关。在住院期间，磺达肝癸钠与依诺肝素应用于NSTE-ACS保守治疗的老年患者，有较为相当的临床疗效，但磺达肝癸钠比伊诺肝素的抗凝治疗更安全。</p></sec><sec id="s9"><title>文章引用</title><p>李 喆,术 超,管甲亮,王永彬,张学志,秦桥基,田新涛,荆丽宏,周长勇. 磺达肝癸钠和依诺肝素对NSTE-ACS保守治疗老年患者的临床研究Clinical Study on the Conservative Treatment of NSTE-ACS in Elderly Patients with Sodium Sulfonate and Enoxaparin[J]. 临床医学进展, 2020, 10(11): 2705-2709. https://doi.org/10.12677/ACM.2020.1011411</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38813-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">陈纪林, 郭远林. 冠状动脉介入治疗中不同抗凝药物的疗效及安全性评述[J]. 中国循环杂志, 2011, 26(5): 322-324.</mixed-citation></ref><ref id="hanspub.38813-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016) [J]. 中华心血管病杂志, 2017, 45(5): 359-376.</mixed-citation></ref><ref id="hanspub.38813-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fernández-Bergés, D., Bertomeu-Gonzalez, V., Sánchez, P.L., Cruz-Fernandez, J.M., Arroyo, R., Barriales Álvarez, V., Carrasco Sánchez, F.J., Dalli, E., Castro Beiras, A. and Kaski, J.C. (2010) Clinical Scores and Patient Risk Stratification in Non-ST Elevation Acute Coronary Syndrome. International Journal of Cardiology, 146, 219-224.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2010.04.016</mixed-citation></ref><ref id="hanspub.38813-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">胡盛寿, 高润霖, 刘力生, 朱曼璐, 王文, 王拥军, 吴兆苏, 李惠君, 顾东风, 杨跃进, 郑哲, 陈伟伟. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.</mixed-citation></ref><ref id="hanspub.38813-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">陈卫省, 顾颖, 肖雨尘, 赵仙先, 马丽萍. 2007-2018年住院ST段抬高型心肌梗死和非ST段抬高型心肌梗死患者比例及院内死亡率变化趋势[J/OL]. 第二军医大学学报: 1-10.  
http://kns.cnki.net/kcms/detail/31.1001.R.20200731.1703.006.html, 2020-11-13.</mixed-citation></ref><ref id="hanspub.38813-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">梁文华, 夏豪. 急性非ST段抬高型心肌梗死早期介入与保守治疗效果及预后观察[J]. 临床误诊误治, 2016, 29(3): 106-109.</mixed-citation></ref><ref id="hanspub.38813-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">王寅, 蒋利. 依诺肝素与达肝素用于非介入治疗非ST段抬高型急性冠状动脉综合征患者的短期疗效和安全性对比[J]. 世界临床药物, 2012, 33(1): 30-33+36.</mixed-citation></ref><ref id="hanspub.38813-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">宋莉, 颜红兵, 刘臣, 周鹏, 赵汉军, 刘然, 迟云鹏, 李文峥. 非ST段抬高型急性冠状动脉综合征患者在介入治疗围术期应用磺达肝癸钠与那屈肝素的安全性和疗效比较[J]. 中国循环杂志, 2015, 30(2): 111-115.</mixed-citation></ref><ref id="hanspub.38813-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rapezzi, C., Biagini, E. and Branzi, A. (2008) Guidelines for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal, 29, 277-278.  
&lt;br&gt;https://doi.org/10.1093/eurheartj/ehm498</mixed-citation></ref><ref id="hanspub.38813-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Terres, J.A.R., Lozano-Ortega, G., Kendall, R., et al. (2015) Cost-Effectiveness of Fondaparinux versus Enoxaparin in Non-ST-Elevation Acute Coronary Syndrome in Canada (OASIS-5). BMC Cardiovascular Disorders, 15, Article Number: 180. &lt;br&gt;https://doi.org/10.1186/s12872-015-0175-1</mixed-citation></ref></ref-list></back></article>